Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12345678910111213...2425»
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal, Real-world evidence, Real-world:  Real-world persistence of multiple sclerosis disease-modifying therapies. (Pubmed Central) -  Jun 7, 2024   
    Immune reconstituting DMTs may have the highest potential to offer a single treatment for relapsing MS. Comparative data on DMT persistence and reasons for discontinuation are valuable to inform treatment decisions and in personalizing treatment in MS.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  A case of relapsing anti-GBM disease secondary to alemtuzumab therapy. (Pubmed Central) -  Jun 1, 2024   
    However, 20 months later, the patient re-presented with relapsing anti-GBM disease. Despite aggressive treatment, the patient became dialysis-dependent.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Motor Evoked Potential-A Pilot Study Looking at Reliability and Clinical Correlations in Multiple Sclerosis. (Pubmed Central) -  May 6, 2024   
    P=N/A
    MEPs have excellent intrapatient and intrarater reliability, and TA MEPs significantly and strongly correlated with expanded disability status scale, 6-minute walk, and timed 25-foot walk, whereas biceps MEPs significantly and moderately correlated with nine-hole peg test. Further studies using larger cohorts of MS patients are indicated.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Enrollment closed:  DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) -  May 1, 2024   
    P4,  N=800, Active, not recruiting, 
    in this multicenter study that included 269 patients from Argentina we observed in early HET a significantly lower BOT and higher QoL than patients receiving escalation therapy. Recruiting --> Active, not recruiting
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal, HEOR, Real-world evidence, Real-world:  Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany. (Pubmed Central) -  Mar 25, 2024   
    Medication classification adhered to the German Society of Neurology guidelines and designated fumarates, glatiramer acetate, teriflunomide and interferons as low-efficacy category 1 medications; cladribine and S1P-modulators as medium-efficacy category 2 medications; and alemtuzumab, natalizumab, ocrelizumab, ofatumumab and rituximab (off-label) as high-efficacy category 3 medications...While most individuals started their treatment according to the treat-to-target approach and remained on their initially prescribed medication category, there has been a steadily increasing shift towards the EHT approach since 2020. These insights demonstrate that, while not officially recommended by German guidelines, MS providers increasingly adopt the EHT approach.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    New trial:  ADAs to Alemtuzumab (clinicaltrials.gov) -  Mar 15, 2024   
    P=N/A,  N=15, Active, not recruiting, 
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Retrospective data, Journal, Real-world evidence, Real-world:  Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study. (Pubmed Central) -  Mar 8, 2024   
    The safety profile of alemtuzumab was consistent with previous findings, and no new or unexpected safety signals were observed. As this was an observational and retrospective study, the main limitation of not having all variables comprehensively available for all patients should be considered when interpreting results.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Aggressive Multiple Sclerosis: Clinical Phenotype and Treatment Within a Randomised Clinical Trial of Autologous Haematopoietic Stem Cell Transplantation vs High Efficacy Disease Modifying Treatment (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3218;    
    Design/Star-MS is a multicentre parallel-group rater-blinded randomised controlled trial of aHSCT versus DMT (alemtuzumab, cladribine, ocrelizumab and ofatumumab) of 104 RRMS patients in the United Kingdom. aHSCT is delivered using non-myeloablative conditioning with a cyclophosphamide/anti-thymocyte globulin regimen followed by an unselected autologous graft...StarMS will provide class 1 evidence of the best treatment strategy for patients with aggressive MS thereby enabling future delivery of appropriate treatments early in the disease course when they may be most effective.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis. (Pubmed Central) -  Feb 5, 2024   
    Whilst CD52 is expressed by neutrophils and may contribute to early-onset neutropenia following alemtuzumab treatment, deoxycytidine kinase and CD20 antigen required for activity of cladribine tablets, off-label rituximab, ocrelizumab, ofatumumab and ublituximab are not or only weakly expressed by neutrophils...Neutrophils are short-lived, and their removal may be influenced by drug-associated infections, the killing mechanisms of the therapies and amplified by immune dyscrasia due to influences on neutropoiesis following growth factor rerouting for B cell recovery and cytokine deficits following lymphocyte depletion. This highlights the small but evident neutropenia risks following sustained B cell depletion with some treatments.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal, Adverse events:  Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis. (Pubmed Central) -  Jan 9, 2024   
    Our findings not only complement those observed in short-term clinical trials but also provide new insights that help inform the risk-benefit profile of the DMDs used to treat MS in clinical practice. The results of this study highlight the continued need for long-term, independent safety studies of the DMDs used to treat MS.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis. (Pubmed Central) -  Jan 8, 2024   
    The diagnosis of these entities should be taken into account in patients treated with Alemtuzumab, given the risk of developing severe clinical forms. In moderate-severe forms of GO-ALZ, drugs with anti-IL-6 activity are a safe and effective option.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Bioavailable central nervous system disease-modifying therapies for multiple sclerosis. (Pubmed Central) -  Jan 6, 2024   
    To our knowledge, alemtuzumab, fumarates (dimethyl, diroximel, and monomethyl), glatiramer acetates, interferons, mitoxantrone, natalizumab, ocrelizumab, ofatumumab, and teriflunomide are either limited to the periphery or insufficiently studied to confirm direct central nervous system effects in participants with multiple sclerosis. In contrast, cladribine and sphingosine 1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are central nervous system-penetrant and could have beneficial direct central nervous system properties.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Retrospective data, Review, Journal, Immunomodulating:  Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. (Pubmed Central) -  Jan 4, 2024   
    More than half of the included studies were sponsored by pharmaceutical companies and this may have influenced their results. Further studies should focus on direct comparison between active agents, with follow-up of at least three years, and assess other patient-relevant outcomes, such as quality of life and cognitive status, with particular focus on the impact of sex/gender on treatment effects.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Retrospective data, Review, Journal, Adverse events:  Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. (Pubmed Central) -  Nov 30, 2023   
    At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, future systematic reviews should also include non-randomized studies.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Review, Journal:  Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis. (Pubmed Central) -  Nov 28, 2023   
    The clinical trials of these 4 monoclonal antibodies present a significant gender bias. In most cases, the primary and secondary endpoints are not analyzed according to patient sex, despite the fact that international recommendations include this as a minimum requirement for ensuring scientific validity and obtaining appropriate results for extrapolation to the wider population.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  A new computational workflow to guide personalized drug therapy. (Pubmed Central) -  Nov 21, 2023   
    However, further studies need to be performed. GreatNectoranalysis was able to stratify individual patients into three model meta-patients whose dynamics suggested insight into patient-tailored interventions.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients? (Pubmed Central) -  Sep 19, 2023   
    Escalation and induction/high-efficacy treatments need rigorous magnetic resonance imaging monitoring. Monitoring over the first few years, using the MAGNIMS score or American Academy of Neurology guidelines, considerably improves prediction accuracy and facilitates the selection of patients with relapsing-remitting multiple sclerosis requiring aggressive treatment.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis. (Pubmed Central) -  Sep 11, 2023   
    Dimethyl fumarate (DEFINE) and fingolimod (FREEDOMS I) initially exhibited significant effect on BVL; however, this effect was not confirmed in further clinical trials: CONFIRM and FREEDOMS II, respectively...Our results show that BVL in one of the components of clinical disability worsening, together with other variables (lesion volume and annualized relapse rate). Standardization of atrophy measurement technique as well as harmonization of disability worsening and progression criteria in further clinical trials are of utmost importance as they enable a reliable comparison of neuroprotective potential of DMTs.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Trial completion, Enrollment change:  Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment (clinicaltrials.gov) -  Sep 6, 2023   
    P=N/A,  N=17, Completed, 
    Standardization of atrophy measurement technique as well as harmonization of disability worsening and progression criteria in further clinical trials are of utmost importance as they enable a reliable comparison of neuroprotective potential of DMTs. Unknown status --> Completed | N=60 --> 17